Tag
This cohort study of 6,638 T3b differentiated thyroid cancer patients found no survival benefit from adjuvant radioactive iodine therapy, suggesting the need for individualized treatment strategies and prospective studies focusing on recurr
A novel protocol performing diagnostic 131I scans within 24 hours after the second rhTSH injection reliably guides radioiodine therapy in differentiated thyroid cancer, enabling same-cycle pre-treatment evaluation and treatment without sche
A nationwide prospective study identifies early fatigue and poor mental health as key predictors of long-term fatigue in differentiated thyroid cancer patients, while thyrotropin suppression shows no association with fatigue.
Pediatric and young adult survivors of differentiated thyroid cancer face a significant long-term risk of second primary malignancies, especially with radioactive iodine treatment, highlighting the need for extended surveillance and tailore
A prospective cohort study suggests that differentiated thyroid cancer patients with sustained excellent response after at least 5 years of specialist follow-up can be safely transitioned to primary care with very low recurrence risk.
In radioiodine-avid metastatic differentiated thyroid cancer, rhTSH and mixed rhTSH/thyroid hormone withdrawal preparation produced comparable adjusted outcomes. Prognosis was driven mainly by metastatic burden and age, supporting individua
Study finds long-term TSH suppression in postmenopausal women with thyroid cancer correlates with poorer cardiovascular health, reduced quality of life, and increased osteoporosis risk compared to controls.
The IoN trial demonstrates that postoperative radioiodine ablation can be safely omitted in most patients with low-risk differentiated thyroid cancer after total thyroidectomy, without compromising recurrence-free survival.
